Comparative Pharmacology
Head-to-head clinical analysis: LOESTRIN FE 1 20 versus NORCEPT E 1 35 28.
Head-to-head clinical analysis: LOESTRIN FE 1 20 versus NORCEPT E 1 35 28.
LOESTRIN FE 1/20 vs NORCEPT-E 1/35 28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive consisting of ethinyl estradiol and norethindrone acetate. Inhibits gonadotropin secretion (FSH, LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Increases cervical mucus viscosity and alters endometrial structure, impeding sperm penetration and implantation.
Combination estrogen (ethinyl estradiol) and progestin (norethindrone) contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, and alters endometrial lining.
One tablet (norethindrone acetate 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 consecutive days, followed by one ferrous fumarate tablet (75 mg) orally once daily for 7 days.
1 tablet orally once daily for 21 days, followed by 7 days of placebo tablets.
None Documented
None Documented
Norethindrone: 6-9 hours (terminal). Ethinyl estradiol: 13-27 hours (terminal, mean 16 hours). Steady-state reached within 5-7 days.
Norethindrone: 5-14 hours; ethinyl estradiol: 13-27 hours. The terminal half-life of norethindrone is about 10 hours, allowing once-daily dosing; ethinyl estradiol's longer half-life contributes to steady-state concentrations within 3-5 days.
Norethindrone: 50-60% renal (as metabolites), 20-30% fecal. Ethinyl estradiol: 40-50% renal (as glucuronide conjugates), 30-40% fecal (as sulfate conjugates).
Renal (primarily as metabolites) and fecal; approximately 50-60% excreted in urine, 30-40% in feces. Ethinyl estradiol and norethindrone are extensively metabolized via hydroxylation and conjugation; glucuronide and sulfate conjugates are eliminated in urine and bile.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive